Skip to main content
logo
Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
4.620
-0.120 (-2.53%)
Jul 30, 2026, 10:12 AM EDT - Market open

Foghorn Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
28.2230.9122.634.1619.231.32
Revenue Growth
20.08%36.75%-33.83%77.63%1357.77%206.74%
Gross Profit
28.2230.9122.634.1619.231.32
Operating Income
-85.05-86.39-102.68-107.91-117.14-100.73
Net Income
-75.32-74.28-86.62-98.43-108.88-101.32
Earnings Per Share
-1.16-1.18-1.58-2.34-2.62-2.73
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
183.63158.89243.75234.06345.8154.29
Total Debt
41.9941.2737.1345.0751.5158.33
Net Cash (Debt)
141.64117.62206.62188.98294.2995.96
Net Cash Growth
-23.74%-43.07%9.33%-35.78%206.69%-7.53%
Net Cash Per Share
2.191.873.764.507.082.58

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-87.4-86.1-100.41-118.11193.61-50.25
Capital Expenditures
-0.02-0.05-0.91-1.22-1.21-3.31
Free Cash Flow
-87.42-86.15-101.31-119.33192.4-53.56
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-301.34%-279.50%-454.31%-315.93%-609.20%-7637.15%
Pretax Margin
-266.88%-240.33%-383.24%-275.80%-566.27%-7494.62%
Profit Margin
-266.88%-240.33%-383.24%-263.43%-566.27%-7494.62%
FCF Margin
-309.73%-278.72%-448.24%-349.38%1000.63%-4060.88%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
P/FCF Ratio
----1.39-
PS Ratio
9.869.9011.617.9813.87716.09